These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26498662)

  • 1. The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype.
    Need EF; Selth LA; Trotta AP; Leach DA; Giorgio L; O'Loughlin MA; Smith E; Gill PG; Ingman WV; Graham JD; Buchanan G
    BMC Cancer; 2015 Oct; 15():791. PubMed ID: 26498662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
    Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
    Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.
    Knutson TP; Truong TH; Ma S; Brady NJ; Sullivan ME; Raj G; Schwertfeger KL; Lange CA
    J Hematol Oncol; 2017 Apr; 10(1):89. PubMed ID: 28412963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells.
    Reddel RR; Alexander IE; Koga M; Shine J; Sutherland RL
    Cancer Res; 1988 Aug; 48(15):4340-7. PubMed ID: 3390830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
    Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
    J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen.
    Katzenellenbogen BS; Norman MJ
    Endocrinology; 1990 Feb; 126(2):891-8. PubMed ID: 2404751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
    McFall T; McKnight B; Rosati R; Kim S; Huang Y; Viola-Villegas N; Ratnam M
    J Biol Chem; 2018 Jan; 293(4):1163-1177. PubMed ID: 29162724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
    Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
    Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
    Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
    Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.
    Sarvilinna N; Eronen H; Miettinen S; Vienonen A; Ylikomi T
    Int J Cancer; 2006 Feb; 118(4):832-40. PubMed ID: 16152593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor.
    Moore NL; Hanson AR; Ebrahimie E; Hickey TE; Tilley WD
    J Steroid Biochem Mol Biol; 2020 May; 199():105548. PubMed ID: 31805393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
    Liang Y; Wu J; Stancel GM; Hyder SM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.
    Cui X; Lazard Z; Zhang P; Hopp TA; Lee AV
    Oncogene; 2003 Oct; 22(44):6937-41. PubMed ID: 14534541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-estrogenic effect of unliganded progesterone receptor is estrogen-selective in breast cancer cells MCF-7.
    Zheng ZY; Lin VC
    Cancer Lett; 2008 Sep; 268(2):202-11. PubMed ID: 18477500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.